Menopause Age and Anxiety-Depression
Key facts
- Who runs it
- Ankara City Hospital Bilkent
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 136 people enrolled
- Started
- 15 Dec 2024
- Ended
- 15 Sept 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- Beck Anxıety Inventory (BAI)
- State-Trait Anxiety Scale (STAI) 1-2
- Record updated
- 19 December 2025
Who can take part
- Age
- 24 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Healthy women over 24 years of age who visited our hospital for routine outpatient check-ups, had been diagnosed with menopause, and had no history of psychiatric disorders before menopause
Who cannot take part
- Cardiovascular diseases including hypertension
- Type 1 or type 2 diabetes mellitus
- Primary adrenal insufficiency
- Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
- Renal insufficiency
- Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
- Neurologic diseases
- Psychiatric disorders
- Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever
- History of any malignancy
- History of exposure to chemotherapeutic agents or radiotherapy
- Individuals with a history of chronic or regular medication use that could cause anxiety or depression symptoms
- Individuals with a personal history of psychiatric disorders
- Individuals with a history of depression in the past 6 months
- Morbid obesity
- Uterine fibroids
- Hepatic dysfunctions
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Menopause is defined as the permanent cessation of menstrual cycles due to ovarian follicle depletion, typically occurring after age 50, and is associated with decreased estrogen levels. Primary ovarian insufficiency (POI) involves early ovarian dysfunction before age 40, with infertility as a key concern. Both menopause and POI may contribute to psychological symptoms, including anxiety and depression, influenced by sociodemographic and health factors. While literature reports anxiety in middle-aged women, data on its association with menopausal timing are limited. This study aims to compare women with POI and those undergoing natural menopause after age 40, assessing the relationship between age at menopause, anxiety, and depression, as well as the impact of fertility expectations on psychological well-being in POI patients.
The 2 groups in the trial
- Menopause group
Patients over 40 years of age who have undergone menopause and who visited our hospital's obstetrics and gynecology outpatient clinic for routine check-ups, without any additional diseases or complaints.
Treatment: Beck Anxıety Inventory (BAI) and State-Trait Anxiety Scale (STAI) 1-2
- Primary ovarian insufficiency (POI) group
Patients who experienced menopause before the age of 40 and who visited our hospital's obstetrics and gynecology outpatient clinic for routine check-ups, without any additional diseases or complaints.
Treatment: Beck Anxıety Inventory (BAI) and State-Trait Anxiety Scale (STAI) 1-2
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Association Between Age at Menopause and Levels of Anxiety and Depression
- Record updated
- 19 December 2025